Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allovectin-7 plus Dacarbazine in Metastatic Melanoma
NCT00003647Phase 3Completed
- Sponsor
- Vical Incorporated
- Start
- Jul 1998
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allovectin-7 in melanoma (2 arms), sponsored by Vical Incorporated. Primary endpoints: Time to Disease Progression and Objective Clinical Response Rate. Started Jul 1998; status: completed.
02
Drugs
allovectin-7
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003647.